DOCSLIB.ORG

Gdnf, Neurturin and Artemin Activate and Sensitize Bone Afferent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Gdnf, Neurturin and Artemin Activate and Sensitize Bone Afferent This Accepted Manuscript has not been copyedited and formatted. The final version may differ from this version. Research Articles: Neurobiology of Disease Gdnf, Neurturin and Artemin Activate and Sensitize Bone Afferent Neurons and Contribute To Inflammatory Bone Pain Sara Nencini, Mitchell Ringuet, Dong-Hyun Kim, Claire Greenhill and Jason J Ivanusic Department of Anatomy and Neuroscience, University of Melbourne. DOI: 10.1523/JNEUROSCI.0421-18.2018 Received: 15 February 2018 Revised: 20 March 2018 Accepted: 22 April 2018 Published: 30 April 2018 Author contributions: S.N. and J.J.I. edited the paper; J.J.I. wrote the first draft of the paper; J.J.I. designed research; S.N., M.R., D.-H.K., C.G., and J.J.I. performed research; J.J.I. contributed unpublished reagents/ analytic tools; S.N., M.R., D.-H.K., C.G., and J.J.I. analyzed data; J.J.I. wrote the paper. Conflict of Interest: The authors declare no competing financial interests. This work was supported by funding from the Australian National Health and Medical Research Council, a Clive and Vera Ramaciotti Foundation Establishment Grant, and a Medical Research and Technology Grant from Australian and New Zealand Charitable Trustees. The authors have no conflicts of interest. The authors acknowledge Associate Professor James Brock for his comments on the manuscript. Corresponding Author: Associate Professor Jason Ivanusic, Department of Anatomy and Neuroscience, University of Melbourne, Melbourne, VIC 3010, Australia, Tel: +61 3 8344 7254, Fax +61 3 9347 5219, Email: [email protected] Cite as: J. Neurosci ; 10.1523/JNEUROSCI.0421-18.2018 Alerts: Sign up at www.jneurosci.org/cgi/alerts to receive customized email alerts when the fully formatted version of this article is published. Accepted manuscripts are peer-reviewed but have not been through the copyediting, formatting, or proofreading process. Copyright © 2018 the authors 1 TITLE: 2 Gdnf, Neurturin and Artemin Activate and Sensitize Bone Afferent Neurons and Contribute 3 To Inflammatory Bone Pain 4 5 ABBREVIATED TITLE: 6 Gdnf, Neurturin and Artemin Signaling In Bone Pain 7 8 AUTHOR NAMES: Sara Nencini, Mitchell Ringuet, Dong-Hyun Kim, Claire Greenhill and 9 Jason J Ivanusic 10 11 AFFILIATIONS: 12 Department of Anatomy and Neuroscience, University of Melbourne. 13 14 CORRESPONDING AUTHOR: 15 Associate Professor Jason Ivanusic, 16 Department of Anatomy and Neuroscience, 17 University of Melbourne, 18 Melbourne, VIC 3010, Australia 19 Tel: +61 3 8344 7254 20 Fax +61 3 9347 5219 21 Email: [email protected] 22 23 NUMBER OF PAGES: 38 24 NUMBER OF FIGURES: 6 25 NUMBER OF TABLES: 3 26 NUMBER OF WORDS: Abstract = 155, Introduction = 649, Discussion = 1510 1 27 28 CONFLICT OF INTEREST: 29 The authors declare no competing financial interests. 30 31 ACKNOWLEDGEMENTS: 32 This work was supported by funding from the Australian National Health and Medical 33 Research Council, a Clive and Vera Ramaciotti Foundation Establishment Grant, and a 34 Medical Research and Technology Grant from Australian and New Zealand Charitable 35 Trustees. The authors have no conflicts of interest. The authors acknowledge Associate 36 Professor James Brock for his comments on the manuscript. 37 38 KEY WORDS 39 Bone; Bone pain; Skeletal; Skeletal Pain; Artemin, Neurturin, GDNF; GFL; Inflammatory 40 pain 41 42 ABSTRACT 43 Pain associated with skeletal pathology or disease is a significant clinical problem, but the 44 mechanisms that generate and/or maintain it remain poorly understood. In this study, we 45 explored roles for GDNF, neurturin and artemin signaling in bone pain using male Sprague- 46 Dawley rats. We have shown that inflammatory bone pain involves activation and 47 sensitization of peptidergic, NGF-sensitive neurons via artemin/GFRD3 signaling pathways, 48 and that sequestering artemin might be useful to prevent inflammatory bone pain derived 49 from activation of NGF-sensitive bone afferent neurons. In addition, we have shown that 50 inflammatory bone pain also involves activation and sensitization of non-peptidergic neurons 51 via GDNF/GFRD1 and neurturin/GFRD2 signaling pathways, and that sequestration of 2 52 neurturin, but not GDNF, might be useful to treat inflammatory bone pain derived from 53 activation of non-peptidergic bone afferent neurons. Our findings suggest that GDNF family 54 ligand signaling pathways are involved in the pathogenesis of bone pain and could be targets 55 for pharmacological manipulations to treat it. 56 57 SIGNIFICANCE STATEMENT 58 Pain associated with skeletal pathology, including bone cancer, bone marrow edema 59 syndromes, osteomyelitis, osteoarthritis, and fractures causes a major burden (both in terms 60 of quality of life and cost) on individuals and health care systems worldwide. We have shown 61 the first evidence of a role for GDNF, neurturin and artemin in the activation and 62 sensitization of bone afferent neurons, and that sequestering these ligands reduces pain 63 behavior in a model of inflammatory bone pain. Thus, GDNF family ligand signaling 64 pathways are involved in the pathogenesis of bone pain and could be targets for 65 pharmacological manipulations to treat it. 3 66 INTRODUCTION 67 Pain associated with skeletal pathology, including bone cancer, bone marrow edema 68 syndromes, osteomyelitis, osteoarthritis, and fractures causes a major burden (both in terms 69 of quality of life and cost) on individuals and health care systems worldwide. This burden is 70 expected to increase with advances in modern medicine that prolong life expectancy, because 71 many of the conditions that cause bone pain develop late in life. A dominant feature common 72 to almost all conditions that produce bone pain is the release of inflammatory mediators by 73 cells associated with the disease (Bennett, 1988; Goldring, 2000; Haegerstam, 2001; Mantyh, 74 2004; Urch, 2004; Starr et al., 2008; Berenbaum). Opioids and non-steroidal anti- 75 inflammatory drugs (NSAIDs) are generally used to treat mild to severe inflammatory pain, 76 but therapeutic use for bone pain is limited by side effects associated with prolonged use, and 77 because they may interfere with bone remodeling/healing (Bove et al., 2009; Pountos et al., 78 2012; Chrastil et al., 2013). There is a clear need to find alternative strategies to treat bone 79 pain that do not involve the use of NSAIDs or opioids, and are targeted more specifically at 80 mechanisms that generate and/or maintain inflammatory bone pain. 81 82 Nociceptors can be classified into two groups based on their response to nerve growth factor 83 (NGF) or glial cell line-derived neurotrophic factor (GDNF) (Molliver et al., 1995; Snider 84 and McMahon, 1998). Much is known of the role of NGF in inflammatory pain, and this has 85 led to the development of NGF sequestration to treat inflammatory pain, including that 86 associated with bone pathologies. Sequestering NGF by systemic administration of anti-NGF 87 antibodies reduces pain-like behaviors in animal models of bone cancer and fracture-induced 88 pain (Sevcik et al., 2005; Jimenez-Andrade et al., 2007; Koewler et al., 2007), and also 89 inflammatory pain of other tissue systems (Woolf et al., 1994; Ma and Woolf, 1997; Woolf et 90 al., 1997). Furthermore, clinical trials reveal that they resolve pain in at least some human 91 inflammatory pain conditions (Kumar and Mahal, 2012). However, many osteoarthritic 4 92 patients receiving anti-NGF antibodies in a clinical trial developed rapidly progressive 93 osteoarthritis, particularly when used in conjunction with NSAIDs (Seidel et al., 2013; 94 Hochberg, 2015). We propose that manipulation of signaling through the GDNF family of 95 ligands might constitute an alternative target for therapeutic treatment of inflammatory bone 96 pain. 97 98 The GDNF family of ligands (GFLs: GDNF, neurturin, artemin and persephin) act through 99 the receptor tyrosine kinase RET and one of four accessory subunits (GFRD1-4) which confer 100 ligand specificity for the receptor complexes (GDNF/GFRD1, neurturin/GFRD2, 101 artemin/GFRD3, persephin/GFRD4) (Lindsay and Yancopoulos, 1996; Sah et al., 2005). 102 Further specificity of ligand actions is conferred by restricted expression patterns: GFRD1 103 and GFRD2 are confined mostly to non-peptidergic small diameter GDNF-sensitive sensory 104 neurons (Bennett et al., 1998) whereas GFRD3 is found principally in a sub-population of 105 peptidergic small diameter NGF-sensitive sensory neurons (Orozco et al., 2001) that are 106 likely to be artemin-sensitive. GFRD4 is not found in peripheral sensory neurons. There is 107 documented heterogeneity of GFL receptor expression in sensory neurons projecting to 108 different target tissues (Dolatshad and Saffrey, 2007; Malin et al., 2011), but whether this is 109 true of bone afferent neurons is yet to be determined. There is accumulating evidence for a 110 role of GFL signaling in pain (Lindsay and Yancopoulos, 1996; Sah et al., 2005; Bespalov 111 and Saarma, 2007), and there is evidence that the GFLs and GDNF-sensitive neurons 112 contribute to inflammatory pain (Amaya et al., 2004; Lindfors et al., 2006; Jeon et al., 2008; 113 Malin and Davis, 2008). Of key relevance is the finding that GFL levels are increased by 114 inflammation of peripheral tissues in both humans (Okragly et al., 1999; von Boyen et al., 115 2006) and animals (Amaya et al., 2004; Hashimoto et al., 2005; Malin et al., 2006; Ikeda- 116 Miyagawa et al., 2015). In this study, we show evidence of interactions for each of the GFLs 5 117 with bone afferent neurons, and that blocking some of these interactions prevents 118 inflammatory bone pain. 119 120 METHODS 121 Male Sprague Dawley rats weighing between 200-350 g were used in this study. Animals 122 were housed in pairs or groups of four, in a 12/12 hour light/dark cycle, and were provided 123 with food and water ad libitum.
Load more

Recommended publications
  • Differential Effects of Th1, Monocyte/Macrophage and Th2
    Wayne State University Wayne State University Associated BioMed Central Scholarship 2007 Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins Robert P. Lisak Wayne State University School of Medicine, [email protected] Joyce A. Benjamins Wayne State University School of Medicine, [email protected] Beverly Bealmear Wayne State University School of Medicine, [email protected] Liljana Nedelkoska Wayne State University School of Medicine, [email protected] Bin Yao Applied Genomics Technology Center, Wayne State University, [email protected] Recommended Citation Lisak et al. Journal of Neuroinflammation 2007, 4:30 doi:10.1186/1742-2094-4-30 Available at: http://digitalcommons.wayne.edu/biomedcentral/155 This Article is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Associated BioMed Central Scholarship by an authorized administrator of DigitalCommons@WayneState. See next page for additional authors Authors Robert P. Lisak, Joyce A. Benjamins, Beverly Bealmear, Liljana Nedelkoska, Bin Yao, Susan Land, and Diane Studzinski This article is available at DigitalCommons@WayneState: http://digitalcommons.wayne.edu/biomedcentral/155 Journal of Neuroinflammation BioMed Central Research Open Access Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures
    [Show full text]
  • The GDNF Family: a Role in Cancer? Graeme C
    Volume 20 Number 1 January 2018 pp. 99–117 99 www.neoplasia.com The GDNF Family: A Role in Cancer? Graeme C. Fielder*, 1, 2, Teresa Wen-Shan Yang*, 1, Mahalakshmi Razdan†, Yan Li†, Jun Lu†, Jo K. Perry‡, Peter E. Lobie§ and Dong-Xu Liu† *University of Auckland, Auckland, New Zealand; †The Centre for Biomedical and Chemical Sciences, School of Science, Faculty of Health and Environmental Sciences, Auckland University of Technology, Auckland, New Zealand; ‡Liggins Institute, University of Auckland, Auckland, New Zealand; §Cancer Science Institute of Singapore and Department of Pharmacology, National University of Singapore, Singapore; Tsinghua Berkeley Shenzhen Institute, Tsinghua University, Shenzhen, Guangdong, P. R. China Abstract The glial cell line–derived neurotrophic factor (GDNF) family of ligands (GFLs) comprising of GDNF, neurturin, artemin, and persephin plays an important role in the development and maintenance of the central and peripheral nervous system, renal morphogenesis, and spermatogenesis. Here we review our current understanding of GFL biology, and supported by recent progress in the area, we examine their emerging role in endocrine-related and other non–hormone-dependent solid neoplasms. The ability of GFLs to elicit actions that resemble those perturbed in an oncogenic phenotype, alongside mounting evidence of GFL involvement in tumor progression, presents novel opportunities for therapeutic intervention. Neoplasia (2018) 20, 99–117 Introduction GFL Signaling The glial cell line–derived neurotrophic factor (GDNF) family of Each member of the GDNF family is expressed as a pre-pro-precursor ligands (GFLs) is comprised of four structurally related factors: protein, which is proteolytically cleaved at a putative furin-like GDNF,neurturin(NRTN),artemin(ARTN),andpersephin cleavage site (RAAR) by yet unidentified enzymes to generate an (PSPN) [1–3].
    [Show full text]
  • GDNF Family Ligands and DRG Sensory Neurons 4337
    Development 127, 4335-4344 (2000) 4335 Printed in Great Britain © The Company of Biologists Limited 2000 DEV1547 Positive and negative interactions of GDNF, NTN and ART in developing sensory neuron subpopulations, and their collaboration with neurotrophins Christel Baudet1, Åsa Mikaels1, Heiner Westphal2, Jens Johansen3, Teit E. Johansen3 and Patrik Ernfors1,* 1Laboratory of Molecular Neurobiology, Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden 2Laboratory of Mammalian Genes and Development, National Institute of Health, Bethesda, MD 20892, USA 3NsGene A/S, DK-2570 Ballerup, Denmark *Author for correspondence (e-mail: [email protected]) Accepted 25 July; published on WWW 26 September 2000 SUMMARY Glial cell line-derived neurotrophic factor (GDNF), family receptors are medium sized, whereas small-caliber neurturin (NTN) and neublastin/artemin (ART) are distant nociceptive cells preferentially express a single receptor. In members of the transforming growth factor β family, contrast to brain-derived neurotrophic factor (BDNF)- and have been shown to elicit neurotrophic effects upon dependent neurons, embryonic nerve growth factor (NGF)- several classes of peripheral and central neurons. Limited dependent nociceptive neurons switch dependency to information from in vitro and expression studies has GDNF, NTN and ART postnatally. Neurons that survive in also substantiated a role for GDNF family ligands in the presence of neurotrophin 3 (NT3) or neurotrophin 4 mammalian somatosensory neuron development. Here, we (NT4), including proprioceptive afferents, Merkel end show that although dorsal root ganglion (DRG) sensory organs and D-hair afferents, are also supported by GDNF neurons express GDNF family receptors embryonically, family ligands neonatally, although at postnatal stages they they do not survive in response to their ligands.
    [Show full text]
  • Intravitreal Co-Administration of GDNF and CNTF Confers Synergistic and Long-Lasting Protection Against Injury-Induced Cell Death of Retinal † Ganglion Cells in Mice
    cells Article Intravitreal Co-Administration of GDNF and CNTF Confers Synergistic and Long-Lasting Protection against Injury-Induced Cell Death of Retinal y Ganglion Cells in Mice 1, 1, 1 2 2 Simon Dulz z , Mahmoud Bassal z, Kai Flachsbarth , Kristoffer Riecken , Boris Fehse , Stefanie Schlichting 1, Susanne Bartsch 1 and Udo Bartsch 1,* 1 Department of Ophthalmology, Experimental Ophthalmology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] (S.D.); [email protected] (M.B.); kaifl[email protected] (K.F.); [email protected] (S.S.); [email protected] (S.B.) 2 Research Department Cell and Gene Therapy, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany; [email protected] (K.R.); [email protected] (B.F.) * Correspondence: [email protected]; Tel.: +49-40-7410-55945 A first draft of this manuscript is part of the unpublished doctoral thesis of Mahmoud Bassal. y Shared first authorship. z Received: 9 August 2020; Accepted: 9 September 2020; Published: 11 September 2020 Abstract: We have recently demonstrated that neural stem cell-based intravitreal co-administration of glial cell line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF) confers profound protection to injured retinal ganglion cells (RGCs) in a mouse optic nerve crush model, resulting in the survival of ~38% RGCs two months after the nerve lesion. Here, we analyzed whether this neuroprotective effect is long-lasting and studied the impact of the pronounced RGC rescue on axonal regeneration. To this aim, we co-injected a GDNF- and a CNTF-overexpressing neural stem cell line into the vitreous cavity of adult mice one day after an optic nerve crush and determined the number of surviving RGCs 4, 6 and 8 months after the lesion.
    [Show full text]
  • Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: from Biology to Therapy
    International Journal of Molecular Sciences Review Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy 1, 1, 1,2,3, 3,4 María San Román Gil y, Javier Pozas y, Javier Molina-Cerrillo * , Joaquín Gómez , Héctor Pian 3,5, Miguel Pozas 1, Alfredo Carrato 1,2,3 , Enrique Grande 6 and Teresa Alonso-Gordoa 1,2,3 1 Medical Oncology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain; [email protected] (M.S.R.G.); [email protected] (J.P.); [email protected] (M.P.); [email protected] (A.C.); [email protected] (T.A.-G.) 2 The Ramon y Cajal Health Research Institute (IRYCIS), CIBERONC, 28034 Madrid, Spain 3 Medicine School, Alcalá University, 28805 Madrid, Spain; [email protected] (J.G.); [email protected] (H.P.) 4 General Surgery Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain 5 Pathology Department, Hospital Universitario Ramón y Cajal, 28034 Madrid, Spain 6 Medical Oncology Department, MD Anderson Cancer Center, 28033 Madrid, Spain; [email protected] * Correspondence: [email protected] These authors have contributed equally to this work. y Received: 30 June 2020; Accepted: 10 July 2020; Published: 13 July 2020 Abstract: Thyroid cancer represents a heterogenous disease whose incidence has increased in the last decades. Although three main different subtypes have been described, molecular characterization is progressively being included in the diagnostic and therapeutic algorithm of these patients. In fact, thyroid cancer is a landmark in the oncological approach to solid tumors as it harbors key genetic alterations driving tumor progression that have been demonstrated to be potential actionable targets.
    [Show full text]
  • GDNF, Neurturin, and Artemin Activate and Sensitize Bone Afferent Neurons and Contribute to Inflammatory Bone Pain
    The Journal of Neuroscience, May 23, 2018 • 38(21):4899–4911 • 4899 Neurobiology of Disease GDNF, Neurturin, and Artemin Activate and Sensitize Bone Afferent Neurons and Contribute to Inflammatory Bone Pain X Sara Nencini, XMitchell Ringuet, Dong-Hyun Kim, Claire Greenhill, and XJason J. Ivanusic Department of Anatomy and Neuroscience, University of Melbourne, Parkville 3010, Victoria, Australia Pain associated with skeletal pathology or disease is a significant clinical problem, but the mechanisms that generate and/or maintain it remain poorly understood. In this study, we explored roles for GDNF, neurturin, and artemin signaling in bone pain using male Sprague Dawley rats. We have shown that inflammatory bone pain involves activation and sensitization of peptidergic, NGF-sensitive neurons via artemin/GDNF family receptor ␣-3 (GFR␣3) signaling pathways, and that sequestering artemin might be useful to prevent inflammatory bone pain derived from activation of NGF-sensitive bone afferent neurons. In addition, we have shown that inflammatory bone pain also involves activation and sensitization of nonpeptidergic neurons via GDNF/GFR␣1 and neurturin/GFR␣2 signaling pathways, and that sequestration of neurturin, but not GDNF, might be useful to treat inflammatory bone pain derived from activation of nonpeptidergic bone afferent neurons. Our findings suggest that GDNF family ligand signaling pathways are involved in the pathogenesis of bone pain and could be targets for pharmacological manipulations to treat it. Key words: artemin; bone pain; GDNF; neurturin; pain; skeletal pain Significance Statement Painassociatedwithskeletalpathology,includingbonecancer,bonemarrowedemasyndromes,osteomyelitis,osteoarthritis,and fractures causes a major burden (both in terms of quality of life and cost) on individuals and health care systems worldwide.
    [Show full text]
  • Regulation of GDNF Expression in Sertoli Cells
    157 3 REPRODUCTIONREVIEW Regulation of GDNF expression in Sertoli cells Parag A Parekh1, Thomas X Garcia2,3 and Marie-Claude Hofmann1 1Department of Endocrine Neoplasia, UT MD Anderson Cancer Center, Houston, Texas, USA, 2Department of Pathology and Immunology, Baylor College of Medicine, Houston, Texas, USA, 3Department of Biological and Environmental Sciences, University of Houston-Clear Lake, Houston, Texas, USA Correspondence should be addressed to M-C Hofmann; Email: [email protected] Abstract Sertoli cells regulate male germ cell proliferation and differentiation and are a critical component of the spermatogonial stem cell (SSC) niche, where homeostasis is maintained by the interplay of several signaling pathways and growth factors. These factors are secreted by Sertoli cells located within the seminiferous epithelium, and by interstitial cells residing between the seminiferous tubules. Sertoli cells and peritubular myoid cells produce glial cell line-derived neurotrophic factor (GDNF), which binds to the RET/GFRA1 receptor complex at the surface of undifferentiated spermatogonia. GDNF is known for its ability to drive SSC self- renewal and proliferation of their direct cell progeny. Even though the effects of GDNF are well studied, our understanding of the regulation its expression is still limited. The purpose of this review is to discuss how GDNF expression in Sertoli cells is modulated within the niche, and how these mechanisms impact germ cell homeostasis. Reproduction (2019) 157 R95–R107 Introduction reserve stem cells (A0), coexisting with a population of renewing spermatogonia that they called A1–A4 Proper regulation of stem cell fate is critical to maintain (Clermont & Leblond 1953, Clermont & Bustos-Obregon adequate cell numbers in health and diseases.
    [Show full text]
  • Neuronal Types and Their Specification Dynamics in the Autonomic Nervous System
    From the Department of Medical Biochemistry and Biophysics Karolinska Institutet, Stockholm, Sweden NEURONAL TYPES AND THEIR SPECIFICATION DYNAMICS IN THE AUTONOMIC NERVOUS SYSTEM Alessandro Furlan Stockholm 2016 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by E-Print AB © Alessandro Furlan, 2016 ISBN 978-91-7676-419-0 On the cover: abstract illustration of sympathetic neurons extending their axons Credits: Gioele La Manno NEURONAL TYPES AND THEIR SPECIFICATION DYNAMICS IN THE AUTONOMIC NERVOUS SYSTEM THESIS FOR DOCTORAL DEGREE (Ph.D.) By Alessandro Furlan Principal Supervisor: Opponent: Prof. Patrik Ernfors Prof. Hermann Rohrer Karolinska Institutet Max Planck Institute for Brain Research Department of Medical Biochemistry and Research Group Developmental Neurobiology Biophysics Division of Molecular Neurobiology Examination Board: Prof. Jonas Muhr Co-supervisor(s): Karolinska Institutet Prof. Ola Hermansson Department of Cell and Molecular Biology Karolinska Institutet Department of Neuroscience Prof. Tomas Hökfelt Karolinska Institutet Assistant Prof. Francois Lallemend Department of Neuroscience Karolinska Institutet Division of Chemical Neurotransmission Department of Neuroscience Prof. Ted Ebedal Uppsala University Department of Neuroscience Division of Developmental Neuroscience To my parents ABSTRACT The autonomic nervous system is formed by a sympathetic and a parasympathetic division that have complementary roles in the maintenance of body homeostasis. Autonomic neurons, also known as visceral motor neurons, are tonically active and innervate virtually every organ in our body. For instance, cardiac outflow, thermoregulation and even the focusing of our eyes are just some of the plethora of physiological functions under the control of this system. Consequently, perturbation of autonomic nervous system activity can lead to a broad spectrum of disorders collectively known as dysautonomia and other diseases such as hypertension.
    [Show full text]
  • Multiple Endocrine Neoplasia Type 2: an Overview Jessica Moline, MS1, and Charis Eng, MD, Phd1,2,3,4
    GENETEST REVIEW Genetics in Medicine Multiple endocrine neoplasia type 2: An overview Jessica Moline, MS1, and Charis Eng, MD, PhD1,2,3,4 TABLE OF CONTENTS Clinical Description of MEN 2 .......................................................................755 Surveillance...................................................................................................760 Multiple endocrine neoplasia type 2A (OMIM# 171400) ....................756 Medullary thyroid carcinoma ................................................................760 Familial medullary thyroid carcinoma (OMIM# 155240).....................756 Pheochromocytoma ................................................................................760 Multiple endocrine neoplasia type 2B (OMIM# 162300) ....................756 Parathyroid adenoma or hyperplasia ...................................................761 Diagnosis and testing......................................................................................756 Hypoparathyroidism................................................................................761 Clinical diagnosis: MEN 2A........................................................................756 Agents/circumstances to avoid .................................................................761 Clinical diagnosis: FMTC ............................................................................756 Testing of relatives at risk...........................................................................761 Clinical diagnosis: MEN 2B ........................................................................756
    [Show full text]
  • Artemin-Stimulated Progression of Human Non–Small Cell Lung Carcinoma Is Mediated by BCL2
    Published OnlineFirst June 8, 2010; DOI: 10.1158/1535-7163.MCT-09-1077 Research Article Molecular Cancer Therapeutics Artemin-Stimulated Progression of Human Non–Small Cell Lung Carcinoma Is Mediated by BCL2 Jian-Zhong Tang1, Xiang-Jun Kong3, Jian Kang1, Graeme C. Fielder1, Michael Steiner1, Jo K. Perry1, Zheng-Sheng Wu4, Zhinan Yin5, Tao Zhu3, Dong-Xu Liu1, and Peter E. Lobie1,2 Abstract We herein show that Artemin (ARTN), one of the glial cell line–derived neurotrophic factor family of li- gands, promotes progression of human non–small cell lung carcinoma (NSCLC). Oncomine data indicate that expression of components of the ARTN signaling pathway (ARTN, GFRA3, and RET) is increased in neoplas- tic compared with normal lung tissues; increased expression of ARTN in NSCLC also predicted metastasis to lymph nodes and a higher grade in certain NSCLC subtypes. Forced expression of ARTN stimulated survival, anchorage-independent, and three-dimensional Matrigel growth of NSCLC cell lines. ARTN increased BCL2 expression by transcriptional upregulation, and inhibition of BCL2 abrogated the oncogenic properties of ARTN in NSCLC cells. Forced expression of ARTN also enhanced migration and invasion of NSCLC cells. Forced expression of ARTN in H1299 cells additionally resulted in larger xenograft tumors, which were high- ly proliferative, invasive, and metastatic. Concordantly, either small interfering RNA–mediated depletion or functional inhibition of endogenous ARTN with antibodies reduced oncogenicity and invasiveness of NSCLC cells. ARTN therefore mediates progression of NSCLC and may be a potential therapeutic target for NSCLC. Mol Cancer Ther; 9(6); 1697–708. ©2010 AACR. Introduction Therefore, identification and subsequent targeting of novel oncogenic pathways may provide an advantage to Lung carcinoma is currently responsible for the highest the current regimens used to treat lung carcinoma and cancer-related mortality worldwide, with overall 5-year consequently improve prognosis.
    [Show full text]
  • Developing Therapeutically More Efficient Neurturin Variants For
    Neurobiology of Disease 96 (2016) 335–345 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Developing therapeutically more efficient Neurturin variants for treatment of Parkinson's disease Pia Runeberg-Roos a,⁎, Elisa Piccinini a,1,Anna-MaijaPenttinena,1, Kert Mätlik a, Hanna Heikkinen a, Satu Kuure a,2, Maxim M. Bespalov a,3, Johan Peränen a,4,EnriqueGarea-Rodríguezb,5, Eberhard Fuchs c, Mikko Airavaara a, Nisse Kalkkinen a, Richard Penn d,6, Mart Saarma a a Institute of Biotechnology, University of Helsinki, PB 56 (Viikinkaari 5D), FIN-00014, Finland b Department of Neuroanatomy, Institute for Anatomy and Cell Biology, University of Freiburg, Freiburg, Germany c German Primate Center, Göttingen, Germany d CNS Therapeutics Inc., 332 Minnesota Street, Ste W1750, St. Paul, MN 55101, USA article info abstract Article history: In Parkinson's disease midbrain dopaminergic neurons degenerate and die. Oral medications and deep brain Received 26 May 2016 stimulation can relieve the initial symptoms, but the disease continues to progress. Growth factors that might Revised 4 July 2016 support the survival, enhance the activity, or even regenerate degenerating dopamine neurons have been tried Accepted 13 July 2016 with mixed results in patients. As growth factors do not pass the blood-brain barrier, they have to be delivered Available online 15 July 2016 intracranially. Therefore their efficient diffusion in brain tissue is of crucial importance. To improve the diffusion of the growth factor neurturin (NRTN), we modified its capacity to attach to heparan sulfates in the extracellular Keywords: NRTN matrix. We present four new, biologically fully active variants with reduced heparin binding.
    [Show full text]
  • Expression and Regulation of GFR 3, a Glial Cell Line-Derived Neurotrophic
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 1295–1300, February 1998 Neurobiology Expression and regulation of GFRa3, a glial cell line-derived neurotrophic factor family receptor PHILIPPE NAVEILHAN*, CHRISTEL BAUDET*, ÅSA MIKAELS*, LIYA SHEN†,HEINER WESTPHAL†, AND PATRIK ERNFORS*‡ *Laboratory of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, S17177 Stockholm, Sweden, and †Laboratory of Mammalian Genes and Development, National Institutes of Health, Bethesda, MD 20892 Communicated by Tomas Hokfelt, Karolinska Institute, Stockholm, Sweden, November 26, 1997 (received for review September 22, 1997) ABSTRACT We report the identification of an additional The switch from NT3 dependency is paralleled by the down- member of the glial cell line-derived neurotrophic factor regulation of the NT3 receptor, trkC (25). (GDNF) family receptor, termed GFRa3, that is homologous Recently, a family of neurotrophic factors has been discov- to the previously identified GDNF and neurturin ligand ered, including the structurally related ligands glial cell line- binding receptors GFRa1 and GFRa2. GFRa3 is 32% and 37% derived neurotrophic factor (GDNF) and neurturin (NTN) identical to GFRa1 and GFRa2, respectively. RNase protec- (26, 27). They are distant members to the transforming growth tion assays show that whereas gfra1 and gfra2 are abundant factor b family. GDNF is a potent survival factor for several in both developing and adult brain, gfra3 is exclusively populations of central neurons in culture and in vivo. GDNF expressed during development. All receptors are widely protects lesioned adult substantia nigra dopaminergic neurons present in both the developing and adult peripheral nervous from death (26, 28–30) and rescues developing and lesioned system and in peripheral organs.
    [Show full text]